Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

César Serrano(Hebron University), Jonathan A. Fletcher(Brigham and Women's Hospital)
British Journal of Cancer
February 22, 2019
Cited by 165


Related Papers